| Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
0.010 | GeneticVariation | BEFREE | Recently, the rs61752561 SNP (Asp84Asn substitution) in exon 3 of the kallikrein-related peptidase 3 (<i>KLK3</i>) gene encoding prostate-specific antigen (PSA) was reported to be strongly associated with PCa risk (<i>P</i> = 2.3 × 10<sup>-8</sup>). | 30538125 | 2019 |
||||
|
0.010 | GeneticVariation | BEFREE | Furthermore, XB130 knockdown hindered transition of G1 to S phase in prostate cancer cell line DU145 and LNCap, which might contribute to the inhibition of cellular proliferation. | 27509056 | 2016 |
||||
|
0.010 | GeneticVariation | BEFREE | Furthermore, XB130 knockdown hindered transition of G1 to S phase in prostate cancer cell line DU145 and LNCap, which might contribute to the inhibition of cellular proliferation. | 27509056 | 2016 |
||||
|
0.010 | GeneticVariation | BEFREE | Based on these results, we concluded that the p21 C70T polymorphism is associated with decreased risk of prostate cancer in Slovak men. | 23292332 | 2013 |
||||
|
0.010 | GeneticVariation | BEFREE | Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val. | 20735386 | 2011 |
||||
|
0.010 | GeneticVariation | BEFREE | We did not observe a strong association with the KLK3 variant, reported in previous studies to confer risk for prostate cancer (rs2735839; P = 0.20) but did observe three highly correlated SNPs (rs17632542, rs62113212 and rs62113214) associated with prostate cancer [P = 3.41 × 10(-4), per-allele trend odds ratio (OR) = 0.77, 95% CI = 0.67-0.89]. | 21318478 | 2011 |
||||
|
0.010 | GeneticVariation | BEFREE | A link between elevated IL6 and up-regulated S100P in androgen-refractory and metastatic PCa is postulated. | 15474988 | 2005 |
||||
|
0.010 | GeneticVariation | BEFREE | Three prostate cancer-derived p53 mutants (F134L, M237L, R273H) were introduced into LNCaP prostate cancer cells and stable transfectants established. | 14587098 | 2003 |